drugset / Trial / NCT00292981

C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)

NCT00292981

Phase 3 Completed 57 enrolled CSL Behring
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Hereditary angioedema (HAE) is a rare disorder characterized by congenital lack of functional C1 esterase inhibitor. If not treated adequately, the acute attacks of HAE can be life-threatening and may even result in fatalities, especially in case of involvement of the larynx.The planned extension study is designed to enrol subjects that participated in the pivotal study in order to provide them with C1-INH for treatment of acute HAE attacks for 24 months or until the licensing procedure for C1-INH is finalized, whatever comes first.

Timeline

Start
2005-08
Primary completion
2010-02
Completion
2010-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CINRYZE Protein / enzyme biologic 20 iu/kg Intravenous

Indications